ELECSYS FT3 III
Received Mar 27, 2024 · Event occurred Feb 17, 2024
Report 1823260-2024-00920 · MDR key 18985248
Device
Generic name
Total Triiodothyronine
Manufacturer
Roche DiagnosticsModel number
FT3 IIICatalog number
09005811190
Lot number
ASKU, 737314, 686656
Product problems
- High Test Results
- High Test Results
Patient
58 YR · Male
- No Clinical Signs, Symptoms or Conditions
- No Clinical Signs, Symptoms or Conditions
Narrative
Additional Manufacturer Narrative
THE SERIAL NUMBER OF THE CUSTOMER'S E801 ANALYZER IS (B)(6) . THE FT3 REAGENT LOT NUMBER AND EXPIRATION DATE USED ON THIS ANALYZER WERE REQUESTED, BUT NOT PROVIDED. THE SERIAL NUMBER OF THE E801 ANALYZER USED FOR INVESTIGATION IS (B)(6) . FT3 REAGENT LOT NUMBER 737314, WITH AN EXPIRATION DATE OF 30-NOV-2024 WAS USED ON THIS ANALYZER. THE SERIAL NUMBER OF THE E411 ANALYZER USED FOR INVESTIGATION IS (B)(6) . FT3 REAGENT LOT NUMBER 686656, WITH AN EXPIRATION DATE OF 30-APR-2024 WAS USED ON THIS ANALYZER. THE INVESTIGATION IS ONGOING.
Description of Event or Problem
THE INITIAL REPORTER STATED THEY RECEIVED DISCREPANT RESULTS FOR ONE PATIENT SAMPLE TESTED WITH ELECSYS FT3 III ON TWO COBAS E 801 MODULE ANALYZERS AND A COBAS E 411 ANALYZER. REFER TO THE ATTACHMENT FOR ALL PATIENT DATA. THE SAMPLE WAS INITIALLY TESTED ON THE CUSTOMER'S E801 ANALYZER ON (B)(6)2024. THE SAMPLE WAS REPEATED USING THE WAKO ACCURASEED AND ABBOTT ALINITY METHODS. THE SAMPLE WAS ALSO TREATED WITH A 25% POLYETHYLENE GLYCOL (PEG) SOLUTION AND REPEATED ON THE E801 ANALYZER. THE SAMPLE WAS PROVIDED FOR INVESTIGATION, WHERE IT WAS TESTED ON A SECOND E801 ANALYZER AND AN E411 ANALYZER ON (B)(6) 2024.
Additional Manufacturer Narrative
THE CUSTOMER HAS CLARIFIED THAT THE AFFECTED SAMPLE IS ANOTHER SAMPLE FROM THE SAME PATIENT PREVIOUSLY REPORTED IN MFG REPORT NUMBERS 1823260-2023-00722 AND 1823260-2023-00723. FURTHER INVESTIGATIONS PERFORMED WITH THE AFFECTED PATIENT SAMPLE DETERMINED THAT IT CONTAINS AN INTERFERING FACTOR AGAINST THE RUTHENIUM LABEL COMPONENT OF THE FT3 ASSAY. PER PRODUCT LABELING: "IN RARE CASES, INTERFERENCE DUE TO EXTREMELY HIGH TITERS OF ANTIBODIES TO ANALYTE-SPECIFIC ANTIBODIES, STREPTAVIDIN OR RUTHENIUM CAN OCCUR. THESE EFFECTS ARE MINIMIZED BY SUITABLE TEST DESIGN." THE INVESTIGATION DID NOT IDENTIFY A PRODUCT ISSUE.